VIDEO: A surgeon's perspective on treating hypertrophic cardiomyopathy

Surgical myectomy is the standard of care for treating patients with obstructive hypertrophic cardiomyopathy (HCM), and specialists are exploring new ways to further improve this procedure and define its role in patient management. There has been a rapid, growing interest in HCM since the first drug therapy, mavacamten, was cleared by the FDA in 2022. This is significantly changing how these patients are managed.

HCM surgical expert Nicholas Smedira, MD, MBA, a cardiovascular surgeon at Cleveland Clinic, spoke with Cardiovascular Business about the role of myectomy at the American Society of Echocardiography (ASE) sponsored HCM Forum in June. The meeting included numerous HCM experts from across the country.